From hypoglycemic drugs to "miracle drugs", in recent years, the popularity of GLP-1 drugs has remained high. With the dual effect of "hypoglycemia" +", a number of GLP-1 drugs have repeatedly "gone out of the circle", and GLP-1 drugs represented by semaglutide have grown rapidly.
According to the latest data from the Report on the Status of Nutrition and Chronic Diseases in China (2020), more than 50% of China's most people are overweight or obese, 19% of children and adolescents aged 6 to 17, and 104% of children under 6 years of age are overweight or obese. In terms of absolute population, there are already 600 million people in the country who are overweight and obese, which is the first in the world.
There are limitations in the safety of traditional weight-loss drugs, and obesity and overweight have been lacking safe and effective means in the clinical practice of China, especially in terms of safe and effective weight control drugs, there is a huge unmet clinical need. GLP-1 products have shown excellent efficacy, safety and multiple benefits in clinical application, making them leaders in the field of diabetes and obesity.
In terms of the diabetes market, according to the International Diabetes Federation (IDF), the number of adult diabetes patients in the world reached 5 in 20213.7 billion, with the largest number of people with diabetes in China, and the number of reported diabetes patients in China in 2021 reached 14.1 billion people, accounting for 26 percent of the total number of reported patients worldwide2%, an increase of 56% in the 10 years from 2011 to 2021, with the improvement of health awareness of Chinese residents and the popularization of disease management, the growth of diabetes is expected to slow down in the future, but it will continue to increase to 16.4 billion people and 17.4 billion people.
In addition to insulin, which occupies a large share of the global diabetes drug sales market, non-insulin drugs are mainly new drugs represented by GLP-1, DPP4 and SGLT2. Type 2 diabetes accounts for about 96% of China, which is the main type of diabetes, and at present, GLP-1 drugs for type 2 diabetes have entered a stage of rapid growth, and there is an opportunity to surpass insulin to occupy a large market.
Tens of billions of anti-sugar and fat loss market, GLP-1 drugs may become the new favorite, are you ready?